|The Rip Van Wrinkler,
Volume XIII, Issue 3, August 2009
Stuff, Stuff, Stuff. . .
Lunetta/Kamen BHE Quilt, Kiafrika Azima, Kiafrika Azima 2, Twin Towers Tight Rope, The Bakers’ Dozen
Signed, limited edition, archival prints of all 5 posters still available.
Club Gear - coming soon, online storefront to order gear embroidered with club images. Stay tuned.
Part of Twin Towers Tight Rope
Collars & Slip Leads
Beautiful collars. “Master’s Pride.”
H.R. Hoerr / LTD Leathergoods
Leather Lure Coursing & Obedience Leashes
760/789-5643 or www.hchltd.com
The Whole Dog Journal
Affordable Agility (equipment)
HiTop Dog Training
High Goal Farm
SitStay.com - Fido Fleece coats
Glitter lure coursing jackets + non-glitter too
www.omahavaccine.com or (800) 367-4444
kvvet.com or (800) 423-8211
Misc. very nice stuff
Melissa Langston Sanford
Hand Made Xpen Covers
William & Shirley Wagner
Metropolitan Museum Store
Dog food online:
Highly recommended books/DVDs:
Temple Grandin - "Animals in Translation"
Patricia McConnell - "The Other End of the Leash"
Turid Rugaas – “On Speaking Terms with Dogs: Calming Signals”
Leslie Nelson – “Really Reliable Recall” (DVD)
Michael Reed Gach – “Acupressure’s Potent Points”
Leslie McDevitt – “Control Unleashed”
Thyroid - W. Jean Dodds DVM – Hemopet
Phone 714-891-2022, fax 714-891-2123
11330 Markon Drive, Garden Grove, CA 92841.
NEW YORK, June 3 (Reuters) - Pfizer Inc's (PFE.N) efforts to develop new cancer drugs have yielded a breakthrough -- for dogs.
The U.S. Food and Drug Administration has approved the first cancer treatment specifically designed to treat dogs, Pfizer and the agency announced on Wednesday. The drug Palladia was approved to treat canine mast cell tumors, a potentially serious type of cancer that accounts for about 20 percent of canine skin tumors, and one that can spread to other parts of the body, including lymph nodes, if not treated.
All cancer drugs now used in veterinary medicine originally were developed for use in humans and are not specifically approved for use in animals, the FDA said. "This cancer drug approval for dogs is an important step forward for veterinary medicine," Bernadette Dunham, director of FDA's Center for Veterinary Medicine, said in a statement. "Prior to this approval, veterinarians had to rely on human oncology drugs without knowledge of how safe or effective they would be for dogs," she said. Pfizer said it would begin selling Palladia in early 2010, but will make the oral drug available to certain veterinary oncology specialists prior to that.
Palladia works by killing tumor cells and by cutting off the blood supply to the tumor. The pill must be taken every other day and the dog will likely have to be on the therapy for several months or longer, depending on tumor response, Pfizer said.
Pfizer declined to divulge the cost of the treatment or to forecast what annual Palladia sales might be. The world's biggest drugmaker said it will likely announce the price of the drug sometime this summer. Treatment with new cancer drugs for humans tends to cost tens of thousands of dollars per patient, and the majority of pet owners do not have health insurance for their dogs. In clinical trials, some 60 percent of dogs treated with Palladia, known chemically as toceranib, had their tumors disappear, shrink or stop growing, Pfizer said. Pfizer Animal Health estimates 1.2 million new canine cancer cases are reported in the United States every year.